Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. (NYSE: GEHC) is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions. The company operates through four main segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Of these, the Imaging segment generates the majority of the company’s revenue.
GE HealthCare is dedicated to providing transformational medical technologies and services that enhance access to quality, affordable healthcare worldwide. Through its cutting-edge products and comprehensive solutions, the company aims to improve patient outcomes and streamline healthcare delivery.
Recent achievements include advancements in artificial intelligence (AI) integration within medical imaging, which supports more accurate and efficient diagnostics. The company is also involved in numerous partnerships with healthcare providers and research institutions to drive innovation and improve global healthcare standards.
Financially, GE HealthCare has showcased robust performance, with steady revenue growth and strong market presence. The company continuously invests in R&D to maintain its edge in the competitive healthcare industry. Their suite of products includes advanced imaging machines, ultrasound devices, patient monitoring systems, and contrast media for diagnostic imaging.
As part of a highly regulated industry, GE HealthCare adheres to strict compliance standards and maintains rigorous quality controls across its operations. The company actively engages with its community, although it reserves the right to monitor and manage public interactions to uphold professional and constructive discourse.
GE HealthCare (GEHC) reported its Q2 2024 financial results, with flat revenues at $4.8 billion year-over-year and 1% organic revenue growth. The net income margin increased slightly to 8.9% from 8.7%, and adjusted EBIT margin rose to 15.3% from 14.8%. Diluted EPS improved to $0.93 from $0.91, while adjusted EPS grew to $1.00 from $0.92. However, the company experienced a decline in cash flow from operating activities to $(119) million from $(67) million and free cash flow to $(182) million from $(136) million.
Segment performance varied, with Imaging revenue down 1%, Ultrasound down 2%, Patient Care Solutions flat, and Pharmaceutical Diagnostics up 12%. GE HealthCare revised its full-year guidance, lowering organic revenue growth to 1-2% from approximately 4%, but raising adjusted EBIT margin to 15.7-16.0% from 15.6-15.9%.
CEO Peter Arduini highlighted strong orders growth in the U.S. and ongoing investments in future growth despite challenges in the China market. The company also announced several strategic collaborations and acquisitions to advance healthcare technologies.
GE HealthCare (GEHC) and Amazon Web Services (AWS) have announced a strategic collaboration to develop generative AI applications for healthcare. GE HealthCare has selected AWS as its strategic cloud provider to build and implement new foundation models aimed at transforming healthcare. The collaboration will utilize AWS services like Amazon Bedrock, Amazon Q Developer, and Amazon SageMaker to accelerate the development of medical technologies and streamline clinical workflows.
The partnership aims to improve diagnostic accuracy, enhance patient outcomes, and promote equitable care. GE HealthCare plans to leverage AWS's healthcare-specific cloud services and generative AI capabilities to build transformative clinical foundation models and applications, potentially reducing application development cycles from years to months.
GE HealthCare (Nasdaq: GEHC) has announced an agreement to acquire Intelligent Ultrasound Group's clinical AI software business for approximately $51 million. This acquisition aims to enhance GE HealthCare's ultrasound portfolio with AI-driven image analysis tools, improving workflow efficiency and ease-of-use for clinicians.
Key highlights include:
- Integration of Intelligent Ultrasound's ScanNav Assist AI technology into GE HealthCare's ultrasound systems
- Addition of R&D experts to drive AI-enabled innovation in Women's Health ultrasound devices
- Support for GE HealthCare's precision care strategy to address inefficiencies and improve patient care quality
The transaction is expected to close in Q4 2024, subject to customary closing conditions.
GE HealthCare (Nasdaq: GEHC) will reveal its second quarter 2024 financial results on July 31, 2024, before the market opens.
The announcement will be followed by a conference call and webcast at 8:30 a.m. Eastern Time, accessible via the company's Investor Relations website.
The webcast, earnings release, and related financial documents will also be available for replay on the same platform.
GE HealthCare Technologies (Nasdaq: GEHC) has announced a cash dividend of $0.03 per share for the second quarter of 2024. This dividend will be payable on August 15, 2024, to shareholders who are on record as of July 19, 2024. The announcement reflects the company’s ongoing commitment to returning value to its shareholders.
Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare have announced the installation of the first Allia Image Guided System (IGS) Pulse in the United States. The Allia IGS Pulse is designed to enhance image quality and workflow in cardiovascular disease diagnosis and treatment. This advanced system will be employed in HHNM's cardiac electrophysiology lab for procedures like cardiac ablations, catheterizations, and valve replacements. Dr. Sean Mazer emphasized the system's ability to handle patients of all sizes and improve surgical outcomes. Brian Miller, CEO of HHNM, noted the hospital's dedication to innovative heart care. Arnaud Marie of GE HealthCare highlighted the collaboration as a testament to GE's commitment to healthcare advancements.
GE HealthCare and MediView XR announced the world's first installation and clinical use of the OmnifyXR Interventional Suite at North Star Vascular and Interventional in Minnesota. The augmented reality-based system, which features a heads-up holographic display, aims to revolutionize interventional radiology by providing advanced imaging, 3D anatomy visualization, and remote collaboration capabilities. The system supports workflow efficiency, improved visualization, and collaborative care. The first clinical procedures using OmnifyXR were the embolization of a genicular artery and a prostate artery. OmnifyXR is currently available in the U.S. and will expand globally.
GE HealthCare (Nasdaq: GEHC) has announced key leadership changes and the realignment of its Imaging and Ultrasound segments. Roland Rott will become the president and CEO of Imaging, while Phil Rackliffe will lead Ultrasound and Image Guided Therapies (IGT). This restructuring, effective July 1, 2024, aims to enhance patient care and business performance. IGT, a $1.6 billion subsegment of Imaging, will merge with Ultrasound in Q3 2024, creating a $5.0 billion global business. Imaging, GE HealthCare’s largest segment, will focus on surgical and interventional procedures, generating over $8.9 billion in annual revenue. The new leadership is expected to drive innovation and growth, leveraging their extensive experience in healthcare and technology.
GE HealthCare has introduced new technologies at the SNMMI 2024 meeting to enhance precision and personalized medicine globally.
The additions include MINItrace Magni, a compact cyclotron for in-house PET tracer production; Omni Legend 21 cm, a versatile PET/CT scanner; and Clarify DL, a deep learning reconstruction tech for clear imaging. These innovations aim to address global healthcare disparities, especially in underserved regions where access to diagnostic imaging is
The company also highlighted its recently acquired MIM Software solutions, which support precise, connected, and efficient care across disease states. A pharmaco-economic study suggests that using a breast oncology PET tracer in diagnostics may save the US healthcare system $142M over five years.
GE HealthCare's study demonstrates that adding a PET/CT scan with the [18F]FES breast oncology tracer to the standard diagnostic process for metastatic or recurrent breast cancer patients could save the US healthcare system $142M over five years. The tracer improves diagnostic accuracy for estrogen receptor (ER) status, especially when biopsy samples are unobtainable or risky, reducing the need for repeated biopsies and ineffective treatments. Published in PLOS ONE, the study shows up to an 8% increase in accurate ER status results. Cerianna, the only FDA-approved [18F]FES PET imaging agent, is now included in the NCCN Clinical Practice Guidelines for certain breast cancer cases, further supporting its clinical and economic benefits.
FAQ
What is the current stock price of GE HealthCare Technologies (GEHC)?
What is the market cap of GE HealthCare Technologies (GEHC)?
What does GE HealthCare Technologies Inc. do?
What are the main business segments of GE HealthCare?
How does GE HealthCare generate most of its revenue?
What recent advancements has GE HealthCare made?
Who are GE HealthCare's partners?
How does GE HealthCare ensure compliance?
What products does GE HealthCare offer?
What is GE HealthCare's commitment to the community?
How has GE HealthCare performed financially?
What is GE HealthCare's mission?
